Chelsea Therapeutics, Inc. to Present Data Demonstrating Efficacy of CH-4051 in Rat Collagen-Induced Arthritis Model at EULAR 2009

CHARLOTTE, N.C., June 11, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a poster highlighting data from the Company's preclinical study of CH-4051, a metabolically inert antifolate, in a Collagen Induced Arthritis (CIA) model will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR) on Saturday, June 13, 2009, in Copenhagen, Denmark.